Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Adicet Bio Inc

ACET ✗ NOT COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: STRONG BUY

Last Close

$8.38

▲ +1.45%

Market Cap $78.45M · Vol 28.14K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$78.45M

Micro Cap

Div Yield

N/A

EPS Growth

+63.11%

YoY

RSI (14)

55.44

Momentum

Beta

1.57

vs Market

52W High

$17.28

51.50% below

52W Low

$6.11

37.15% above

Volume

28.14K

Avg 26.99K

P/B

0.51

Price-to-book

ROE

N/A

Return on equity

Free Float

89.90%

Public shares

Shariah Compliance8 STANDARDS

✗ Adicet Bio Inc (ACET) stock is currently not Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does ACET pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+5.01%

-5.10%

-0.36%

+21.27%

YTD

-0.48%

-19.40%

-75.41%

-93.22%

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-116,803,000.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	N/A
ROA · ROIC	-56.62% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	0.51
P/FCF	N/A
EPS Growth	+63.11%
Outstanding Shares	9.36M

Technical Indicators

50-Day SMA	$8.32
200-Day SMA	$8.22
RSI (14)	55.44
Beta	1.57
52-Week High	$17.28
52-Week Low	$6.11

Volume Today	28.14K
Avg Daily Volume (30D)	26.99K
Relative Volume	1.04x
Volatility (10D)	72.58
Volatility (30D)	68.82
Free Float	89.90%

Analyst Consensus

STRONG BUY

Current Price $8.38

Mean Target $33.17

52W Low$6.11 52W High$17.28

Current

Target

$6.11 $17.28

Current Analyst target

+295.78% upside potential · 6 analysts

Identifiers

ExchangeNasdaq

FIGIBBG00JCXSJQ2

ISINUS0070022076

CountryUnited States of America

Sub-IndustryBiotechnology & Medical Research (NEC)

Earnings DateNov 3, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LONN.S Lonza Group AG -1.78% RVMD Revolution Medicines Inc +0.85% ONC BeOne Medicines AG -2.40% 068270.KS Celltrion Inc -0.50% ABVX Abivax SA -2.05%

Company Profile

Adicet Bio, Inc. is a clinical-stage biotechnology company. It is engaged in advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. Its lead product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases. ADI-001 contains an anti-CD20 CAR that has a proprietary antigen-binding domain that recognizes a region of CD20 distinct from that recognized by rituximab. Its pipeline also includes ADI-270, an investigational allogeneic gamma delta CAR T cell therapy targeting CD70 via the CD27-ligand for the treatment of RCC and with potential in other solid tumor and hematological malignancy indications. Its pipeline has additional internal gamma delta T cell therapy programs in discovery and preclinical development for both hematological malignancies and solid tumors.